Wells Fargo Lifts PT on Insmed Incorporated (INSM) to $130 From $119, Keeps a Buy Rating

Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to buy now. Wells Fargo analyst Tiago Fauth maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) on July 22, raising the associated price target to $130 from $119.

The analyst based the optimistic rating on the company’s potential, stating that it presents a favorable risk/reward scenario for investors with the upcoming approval and launch of Brenso in bronchiectasis and the anticipated clinical developments for the rest of the year.

Fauth also stated that the market opportunity is significant despite the current low expectations, especially with the CRSsNP patient population, which may potentially result in peak sales in the $3 billion range.

The firm added that management has an optimistic outlook on the clinical data, which appears to surpass the minimum required efficacy, further supporting the optimistic rating on Insmed Incorporated (NASDAQ:INSM).

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.